First quarter results from AstraZeneca have disappointed investors, sending shares down on the London Stock Exchange, as the UK firm continued to feel the effects of patent losses on key dr
Boehringer Ingelheim has expanded access to a digital adherence programme that helps COPD patients take their medicines as prescribed by offering them educational and motivational tools.